Gale Smith

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5498095/publications.pdf

Version: 2024-02-01

28	3,376	331670	501196
papers	citations	21 h-index	28 g-index

37	37	37	5934
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase 1â€“2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. New England Journal of Medicine, 2020, 383, 2320-2332.	27.0	1,000
2	SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nature Communications, 2021, 12, 372.	12.8	369
3	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science, 2020, 370, 1089-1094.	12.6	290
4	Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. New England Journal of Medicine, 2021, 384, 2352-2354.	27.0	202
5	NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine, 2020, 38, 7892-7896.	3.8	200
6	Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats. PLoS ONE, 2012, 7, e50852.	2.5	131
7	A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. Journal of Infectious Diseases, 2016, 213, 411-422.	4.0	130
8	Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine, 2013, 31, 524-532.	3.8	118
9	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. Cell Reports Medicine, 2021, 2, 100405.	6.5	110
10	Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine, 2016, 34, 1927-1935.	3.8	106
11	Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine, 2007, 25, 4283-4290.	3.8	86
12	Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine, 2011, 29, 6606-6613.	3.8	85
13	Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults. Immunity and Ageing, 2017, 14, 8.	4.2	62
14	Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine. New England Journal of Medicine, 2018, 378, 2346-2348.	27.0	45
15	Novel hemagglutinin nanoparticle influenza vaccine with Matrix-Mâ„¢ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes. Vaccine, 2017, 35, 5366-5372.	3.8	44
16	Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults. Journal of Infectious Diseases, 2020, 222, 572-582.	4.0	38
17	Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. Scientific Reports, 2016, 6, 24897.	3.3	35
18	Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial. Lancet Infectious Diseases, The, 2022, 22, 73-84.	9.1	35

#	Article	IF	Citations
19	Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs. Vaccine, 2015, 33, 6488-6492.	3.8	27
20	Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection. Vaccine, 2019, 37, 6112-6124.	3.8	25
21	Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Vaccine, 2018, 36, 8069-8078.	3.8	24
22	Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA. Vaccines, 2020, 8, 99.	4.4	24
23	Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-Mâ€“Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine. Clinical Infectious Diseases, 2021, 73, e4278-e4287.	5.8	23
24	Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models. Vaccine, 2017, 35, 4079-4087.	3.8	12
25	Structural Characterization and Modeling of a Respiratory Syncytial Virus Fusion Glycoprotein Nanoparticle Vaccine in Solution. Molecular Pharmaceutics, 2021, 18, 359-376.	4.6	12
26	Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge. Vaccine, 2020, 38, 1258-1270.	3.8	9
27	Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity. Vaccines, 2020, 8, 607.	4.4	8
28	Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein. PLoS ONE, 2019, 14, e0210749.	2.5	7